190 related articles for article (PubMed ID: 28027687)
41. Evaluating the frequency, prognosis and survival of RUNX1 and ASXL1 mutations in patients with acute myeloid leukaemia in northeastern Iran.
Parsa-Kondelaji M; Ayatollahi H; Rostami M; Sheikhi M; Barzegar F; Afzalaghaee M; Moradi E; Sadeghian MH; Momtazi-Borojeni AA
J Cell Mol Med; 2022 Jul; 26(13):3797-3801. PubMed ID: 35692075
[TBL] [Abstract][Full Text] [Related]
42. High Frequency of ASXL1 and IDH Mutations in Young Acute Myeloid Leukemia Egyptian Patients.
El Nahass YH; Nader HA; Sabet S; Nooh HA; Bassiony H; Kamel M; Samra MA; Mahmoud HK; El Metnawy WH; El Refaey FA
Asian Pac J Cancer Prev; 2022 Mar; 23(3):977-984. PubMed ID: 35345371
[TBL] [Abstract][Full Text] [Related]
43. ASXL1 exon 12 mutations are frequent in AML with intermediate risk karyotype and are independently associated with an adverse outcome.
Schnittger S; Eder C; Jeromin S; Alpermann T; Fasan A; Grossmann V; Kohlmann A; Illig T; Klopp N; Wichmann HE; Kreuzer KA; Schmid C; Staib P; Peceny R; Schmitz N; Kern W; Haferlach C; Haferlach T
Leukemia; 2013 Jan; 27(1):82-91. PubMed ID: 23018865
[TBL] [Abstract][Full Text] [Related]
44. Heterogeneous patterns of CEBPalpha mutation status in the progression of myelodysplastic syndrome and chronic myelomonocytic leukemia to acute myelogenous leukemia.
Shih LY; Huang CF; Lin TL; Wu JH; Wang PN; Dunn P; Kuo MC; Tang TC
Clin Cancer Res; 2005 Mar; 11(5):1821-6. PubMed ID: 15756005
[TBL] [Abstract][Full Text] [Related]
45. Chronic Myelomonocytic Leukemia: Focus on Clinical Practice.
Patnaik MM; Tefferi A
Mayo Clin Proc; 2016 Feb; 91(2):259-72. PubMed ID: 26848006
[TBL] [Abstract][Full Text] [Related]
46. Acquired mutations in ASXL1 in acute myeloid leukemia: prevalence and prognostic value.
Pratcorona M; Abbas S; Sanders MA; Koenders JE; Kavelaars FG; Erpelinck-Verschueren CA; Zeilemakers A; Löwenberg B; Valk PJ
Haematologica; 2012 Mar; 97(3):388-92. PubMed ID: 22058207
[TBL] [Abstract][Full Text] [Related]
47. Mutant ASXL1 cooperates with BAP1 to promote myeloid leukaemogenesis.
Asada S; Goyama S; Inoue D; Shikata S; Takeda R; Fukushima T; Yonezawa T; Fujino T; Hayashi Y; Kawabata KC; Fukuyama T; Tanaka Y; Yokoyama A; Yamazaki S; Kozuka-Hata H; Oyama M; Kojima S; Kawazu M; Mano H; Kitamura T
Nat Commun; 2018 Jul; 9(1):2733. PubMed ID: 30013160
[TBL] [Abstract][Full Text] [Related]
48. Myelodysplastic syndromes and acute myeloid leukemia with 17p deletion. An entity characterized by specific dysgranulopoïesis and a high incidence of P53 mutations.
Lai JL; Preudhomme C; Zandecki M; Flactif M; Vanrumbeke M; Lepelley P; Wattel E; Fenaux P
Leukemia; 1995 Mar; 9(3):370-81. PubMed ID: 7885035
[TBL] [Abstract][Full Text] [Related]
49. Pooled analysis of clinical and cytogenetic features in treatment-related and de novo adult acute myeloid leukemia and myelodysplastic syndromes based on a consecutive series of 761 patients analyzed 1976-1993 and on 5098 unselected cases reported in the literature 1974-2001.
Mauritzson N; Albin M; Rylander L; Billström R; Ahlgren T; Mikoczy Z; Björk J; Strömberg U; Nilsson PG; Mitelman F; Hagmar L; Johansson B
Leukemia; 2002 Dec; 16(12):2366-78. PubMed ID: 12454741
[TBL] [Abstract][Full Text] [Related]
50. Targeted Next-Generation Sequencing in Myelodysplastic Syndrome and Chronic Myelomonocytic Leukemia Aids Diagnosis in Challenging Cases and Identifies Frequent Spliceosome Mutations in Transformed Acute Myeloid Leukemia.
Reinig E; Yang F; Traer E; Arora R; Brown S; Rattray R; Braziel R; Fan G; Press R; Dunlap J
Am J Clin Pathol; 2016 Apr; 145(4):497-506. PubMed ID: 27124934
[TBL] [Abstract][Full Text] [Related]
51. Acquired ASXL1 mutations are common in patients with inherited GATA2 mutations and correlate with myeloid transformation.
West RR; Hsu AP; Holland SM; Cuellar-Rodriguez J; Hickstein DD
Haematologica; 2014 Feb; 99(2):276-81. PubMed ID: 24077845
[TBL] [Abstract][Full Text] [Related]
52. Spectrum of molecular defects in juvenile myelomonocytic leukaemia includes ASXL1 mutations.
Sugimoto Y; Muramatsu H; Makishima H; Prince C; Jankowska AM; Yoshida N; Xu Y; Nishio N; Hama A; Yagasaki H; Takahashi Y; Kato K; Manabe A; Kojima S; Maciejewski JP
Br J Haematol; 2010 Jul; 150(1):83-7. PubMed ID: 20408841
[TBL] [Abstract][Full Text] [Related]
53. ASXL1 and SETBP1 mutations and their prognostic contribution in chronic myelomonocytic leukemia: a two-center study of 466 patients.
Patnaik MM; Itzykson R; Lasho TL; Kosmider O; Finke CM; Hanson CA; Knudson RA; Ketterling RP; Tefferi A; Solary E
Leukemia; 2014 Nov; 28(11):2206-12. PubMed ID: 24695057
[TBL] [Abstract][Full Text] [Related]
54. ASXL1 mutations are infrequent in young patients with primary acute myeloid leukemia and their detection has a limited role in therapeutic risk stratification.
El-Sharkawi D; Ali A; Evans CM; Hills RK; Burnett AK; Linch DC; Gale RE
Leuk Lymphoma; 2014 Jun; 55(6):1326-31. PubMed ID: 23952244
[TBL] [Abstract][Full Text] [Related]
55. Asxl1 C-terminal mutation perturbs neutrophil differentiation in zebrafish.
Fang X; Xu S; Zhang Y; Xu J; Huang Z; Liu W; Wang S; Yen K; Zhang W
Leukemia; 2021 Aug; 35(8):2299-2310. PubMed ID: 33483612
[TBL] [Abstract][Full Text] [Related]
56. ASXL1 is a molecular predictor in idiopathic cytopenia of undetermined significance.
Shin DY; Park JK; Kim SM; Im K; Kim JA; Kim SY; Hwang SM; Yoon SS; Lee DS
Leuk Lymphoma; 2019 Mar; 60(3):756-763. PubMed ID: 30301403
[TBL] [Abstract][Full Text] [Related]
57. Loss-of-function Additional sex combs like 1 mutations disrupt hematopoiesis but do not cause severe myelodysplasia or leukemia.
Fisher CL; Pineault N; Brookes C; Helgason CD; Ohta H; Bodner C; Hess JL; Humphries RK; Brock HW
Blood; 2010 Jan; 115(1):38-46. PubMed ID: 19861679
[TBL] [Abstract][Full Text] [Related]
58. Epidemiology and Clinical Significance of Secondary and Therapy-Related Acute Myeloid Leukemia: A National Population-Based Cohort Study.
Granfeldt Østgård LS; Medeiros BC; Sengeløv H; Nørgaard M; Andersen MK; Dufva IH; Friis LS; Kjeldsen E; Marcher CW; Preiss B; Severinsen M; Nørgaard JM
J Clin Oncol; 2015 Nov; 33(31):3641-9. PubMed ID: 26304885
[TBL] [Abstract][Full Text] [Related]
59. Loss of Asxl1 leads to myelodysplastic syndrome-like disease in mice.
Wang J; Li Z; He Y; Pan F; Chen S; Rhodes S; Nguyen L; Yuan J; Jiang L; Yang X; Weeks O; Liu Z; Zhou J; Ni H; Cai CL; Xu M; Yang FC
Blood; 2014 Jan; 123(4):541-53. PubMed ID: 24255920
[TBL] [Abstract][Full Text] [Related]
60. Added prognostic value of secondary AML-like gene mutations in ELN intermediate-risk older AML: ALFA-1200 study results.
Gardin C; Pautas C; Fournier E; Itzykson R; Lemasle E; Bourhis JH; Adès L; Marolleau JP; Malfuson JV; Gastaud L; Raffoux E; Lambert J; Braun T; Thomas X; Chantepie S; Cluzeau T; de Botton S; Berthon C; Boissel N; Duployez N; Terré C; Peffault de Latour R; Michallet M; Celli-Lebras K; Preudhomme C; Dombret H
Blood Adv; 2020 May; 4(9):1942-1949. PubMed ID: 32380535
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
